专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20070197628A1 Cannabinoid receptor modulators 失效
标题翻译：大麻素受体调节剂
公开(公告)号：US20070197628A1
公开(公告)日：2007-08-23
申请号：US11653558
申请日：2007-01-16
申请人： Samuel Chackalamannil , Mariappan Chelliah , Martin Clasby , Keith Eagen , Jack Scott , Yuguang Wang , Yan Xia , William Greenlee
发明人： Samuel Chackalamannil , Mariappan Chelliah , Martin Clasby , Keith Eagen , Jack Scott , Yuguang Wang , Yan Xia , William Greenlee
IPC分类号： A61K31/4035 , C07D209/46
CPC分类号： C07D209/46 , C07C233/31 , C07C233/58 , C07C233/59 , C07C233/60 , C07C233/90 , C07D209/44 , C07D209/52 , C07D211/58 , C07D307/83 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/10
摘要： A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.
摘要翻译：具有式（I）的通式结构的化合物或其药学上可接受的盐，溶剂化物或酯可用于治疗疾病，病症或病症如肥胖，代谢紊乱，成瘾，中枢神经系统疾病，心血管疾病，呼吸系统疾病和胃肠道疾病。

12. 发明申请

US20060007152A1 Computer finger mouse 审中-公开
标题翻译：电脑手指鼠标
公开(公告)号：US20060007152A1
公开(公告)日：2006-01-12
申请号：US11172761
申请日：2005-07-02
申请人： Yuguang Wang
发明人： Yuguang Wang
IPC分类号： G09G5/08
CPC分类号： G06F3/03543 , G06F2203/0333
摘要： A computer finger mouse includes a concave structure for embrace the fingertips of a hand in a relaxed positions. The concave structure allows the mouse be held and manipulated by the fingertips of a hand only. A hand holding and manipulating the computer finger mouse is in a naturally relaxed and curled position, without requiring static twisting of the hand, wrist, or forearm. As a result, fatigue, discomfort, and pain are minimized or eliminated even after a long period of continuous use.
摘要翻译：计算机手指鼠标包括凹形结构，用于在轻松的位置包围手的指尖。凹形结构允许鼠标被手的指尖保持和操纵。握住和操纵计算机手指鼠标的手处于自然松弛和卷曲的位置，而不需要手，手腕或前臂的静态扭转。结果，即使在长时间的连续使用之后，疲劳，不适和疼痛也被最小化或消除。

13. 发明申请

US20050267155A1 Constrained himbacine analogs as thrombin receptor antagonists 有权
标题翻译：约束吗啡类似物作为凝血酶受体拮抗剂
公开(公告)号：US20050267155A1
公开(公告)日：2005-12-01
申请号：US11137283
申请日：2005-05-25
申请人： Mariappan Chelliah , Samuel Chackalamannil , Yan Xia , Martin Clasby , William Greenlee , Yuguang Wang , Enrico Veltri , Wenxue Wu , Michael Graziano , Teddy Kosoglou , Madhu Chintala
发明人： Mariappan Chelliah , Samuel Chackalamannil , Yan Xia , Martin Clasby , William Greenlee , Yuguang Wang , Enrico Veltri , Wenxue Wu , Michael Graziano , Teddy Kosoglou , Madhu Chintala
IPC分类号： A61K31/443 , A61K31/4433 , A61P9/00 , A61P11/00 , A61P25/28 , C07D405/06 , C07D405/08 , C07D493/04 , C07D45/02
CPC分类号： C07D493/04 , C07D405/06
摘要： A compound represented by the structural formula and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line between the ring carbons to which R10 and R34 are attached represents either a single bond or a double bond; the double-dashed line between X and the carbon to which Y is attached represents either a single bond or an absent bond; X is —O— or —NR6— when the double-dashed line represents a single bond; X is H, —OH or —NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.
摘要翻译：公开了由结构式表示的化合物及其药学上可接受的盐和溶剂，其中：R 10和R 34之间的环碳之间的单点划线是附表示单键或双键; X与Y所连接的碳之间的双点划线表示单键或不存在键; 当双点划线表示单键时，X是-O-或-NR 6 - 当双点划线表示不存在的键时，X是H，-OH或-NHR 20; 和其他参数如本文所定义。还公开了含有所述化合物及其作为凝血酶受体拮抗剂和大麻素受体的结合物的药物组合物和组合。

14. 发明申请

US20080090830A1 Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists 有权
标题翻译：双环和三环衍生物作为凝血酶受体拮抗剂
公开(公告)号：US20080090830A1
公开(公告)日：2008-04-17
申请号：US11865793
申请日：2007-10-02
申请人： Samuel Chackalamannil , Mariappan Chelliah , Yuguang Wang , Yan Xia
发明人： Samuel Chackalamannil , Mariappan Chelliah , Yuguang Wang , Yan Xia
IPC分类号： A61K31/4427 , A61K31/435 , A61K31/443 , A61K31/4439 , A61K31/502 , A61P1/00 , A61P11/00 , A61P15/00 , A61P17/00 , A61P35/00 , A61P9/00 , C07D221/06 , C07D401/06 , C07D413/02 , C07D487/00
CPC分类号： C07D401/06 , C07D417/06
摘要： Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：异构体或外消旋混合物的下式的杂环取代三环或其药学上可接受的盐或溶剂合物，其中表示可选的双键，虚线可选地是一个键或没有导致双键或单键的键，如允许通过化合价要求，其中E，A，GM，Het，B，X，R 3，R 10，R 11，本文定义了SUP 32和33 SS，其余取代基如说明书中所定义，以及含有它们的药物组合物和治疗与血栓形成有关的疾病的方法，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心脏衰竭和癌症。还要求与其它心血管药物联合治疗。

15. 发明授权

US07304078B2 Thrombin receptor antagonists 有权
标题翻译：凝血酶受体拮抗剂
公开(公告)号：US07304078B2
公开(公告)日：2007-12-04
申请号：US10412982
申请日：2003-04-14
申请人： Samuel Chackalamannil , William J. Greenlee , Yuguang Wang , Wenxue Wu , Enrico P. Veltri , Yan Xia
发明人： Samuel Chackalamannil , William J. Greenlee , Yuguang Wang , Wenxue Wu , Enrico P. Veltri , Yan Xia
IPC分类号： A61K31/443 , C07D405/02
CPC分类号： C07D405/06 , C07D405/14 , C07D417/14
摘要： Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0–2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1–C6)alkyl, (C3–C8)cycloalkyl, —OH, (C1–C6)alkoxy, R27-aryl(C1–C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3–6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：式中的杂环取代三环

16. 发明授权

US07897601B2 Cannabinoid receptor modulators 失效
标题翻译：大麻素受体调节剂
公开(公告)号：US07897601B2
公开(公告)日：2011-03-01
申请号：US11653558
申请日：2007-01-16
申请人： Samuel Chackalamannil , Mariappan V. Chelliah , Martin C. Clasby , Keith A. Eagen , Jack D. Scott , Yuguang Wang , Yan Xia , William J. Greenlee
发明人： Samuel Chackalamannil , Mariappan V. Chelliah , Martin C. Clasby , Keith A. Eagen , Jack D. Scott , Yuguang Wang , Yan Xia , William J. Greenlee
IPC分类号： A61K31/454 , A61K31/4035 , A61K31/5377 , C07D209/46 , C07D295/04 , C07D401/04
CPC分类号： C07D209/46 , C07C233/31 , C07C233/58 , C07C233/59 , C07C233/60 , C07C233/90 , C07D209/44 , C07D209/52 , C07D211/58 , C07D307/83 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/10
摘要： A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.
摘要翻译：具有式（I）的通式结构的化合物或其药学上可接受的盐，溶剂化物或酯可用于治疗疾病，病症或病症如肥胖，代谢紊乱，成瘾，中枢神经系统疾病，心血管疾病，呼吸系统疾病和胃肠道疾病。

17. 发明授权

US07531544B2 Xanthine phosphodiesterase V inhibitors 失效
公开(公告)号：US07531544B2
公开(公告)日：2009-05-12
申请号：US11852638
申请日：2007-09-10
申请人： Samuel Chackalamannil , Yuguang Wang , Craig D. Boyle , Andrew W. Stamford
发明人： Samuel Chackalamannil , Yuguang Wang , Craig D. Boyle , Andrew W. Stamford
IPC分类号： A61K31/522 , A61P9/12 , A61P15/10 , C07D473/04 , C07D473/06 , C07D473/08
CPC分类号： C07D473/04 , C07D473/06 , C07D473/08
摘要： A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: For example, a representative compound of the invention is:

18. 发明申请

US20070270439A1 THROMBIN RECEPTOR ANTAGONISTS 审中-公开
标题翻译：硫蛋白受体拮抗剂
公开(公告)号：US20070270439A1
公开(公告)日：2007-11-22
申请号：US11774358
申请日：2007-07-06
申请人： Samuel Chackalamannil , Martin Clasby , William Greenlee , Yuguang Wang , Yan Xia , Enrico Veltri , Mariappan Chelliah
发明人： Samuel Chackalamannil , Martin Clasby , William Greenlee , Yuguang Wang , Yan Xia , Enrico Veltri , Mariappan Chelliah
IPC分类号： A61K31/4427 , A61K31/506 , A61P29/00 , A61P35/00 , A61P9/00 , A61P9/02 , A61P9/06 , A61P9/10 , A61P9/12 , C07D221/00 , C07D239/26
CPC分类号： C07D405/06 , C07D405/14 , C07D417/14
摘要： Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0-2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, —OH, (C1-C6)alkoxy, R27-aryl(C1-C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：具有下式的杂环取代的三环或其药学上可接受的盐，其中：虚线表示任选的单键; “img id =”custom-character-00001“he =”2.79mm“wi =”7.03mm“file =”US20070270439A1-20071122-P00002.TIF“img-content =”character“img-format =”tif“/> 表示可选的双键; n为0-2; Q是环烷基，任选被R 13和R 14取代; R 13和R 14独立地选自（C 1 -C 6 -C 6）烷基，（C

19. 发明授权

US07268141B2 Xanthine phosphodiesterase V inhibitors 失效
标题翻译：黄嘌呤磷酸二酯酶V抑制剂
公开(公告)号：US07268141B2
公开(公告)日：2007-09-11
申请号：US10777849
申请日：2004-02-12
申请人： Samuel Chackalamannil , Yuguang Wang , Craig Boyle , Andrew Stamford
发明人： Samuel Chackalamannil , Yuguang Wang , Craig Boyle , Andrew Stamford
IPC分类号： C07D473/08 , C07D473/06 , C07D473/04 , A61K31/522 , A61P15/10
CPC分类号： C07D473/04 , C07D473/06 , C07D473/08
摘要： A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: For example, a representative compound of the invention is:
摘要翻译：具有式（I）的黄嘌呤磷酸二酯酶V抑制剂，具有本文定义的变量，其特别用于治疗男性（勃起）和女性性功能障碍等生理障碍：例如，本发明的代表性化合物是：

20. 发明申请

US20070149518A1 Oxazoloisoquinoline derivatives as thrombin receptor antagonists 有权
标题翻译：恶唑啉异喹啉衍生物作为凝血酶受体拮抗剂
公开(公告)号：US20070149518A1
公开(公告)日：2007-06-28
申请号：US11642170
申请日：2006-12-20
申请人： Samuel Chackalamannil , Yuguang Wang
发明人： Samuel Chackalamannil , Yuguang Wang
IPC分类号： A61K31/538 , A61K31/4745 , C07D491/04
CPC分类号： C07D487/04 , C07D471/04
摘要： Heterocyclic-substituted bi or tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：异构体或外消旋混合物的式I化合物或其药学上可接受的盐或溶剂化物，其中表示可选的双键，虚线是可选的键或无键，导致双键或单键，如价格要求所允许的，并且其中A是N，N，N， N，N，N，R 9，R 10，R 11，本文中定义了11,32，R 32，R 33，B和Het，并且其余取代基如说明书中所定义，以及药物含有它们的组合物和治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和消除相关的疾病的方法通过施用所述化合物。还要求与其它心血管药物联合治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式